• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Irinotecan Actavis 20 mg/ml
    / Abic


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    5 ml x 20 mg/ml

    partial basket chart 2397 9439

    Vial

    15 ml x 20 mg/ml

    partial basket chart 2406 9440

    Vial

    25 ml x 20 mg/ml

    partial basket chart 38369 9604

    Related information


    Dosage

    Dosage must be adjusted individually.


    Indications

    For the treatment of patients with metastatic colorectal cancer:
    In combination with 5-fluorouracil and folinic acid in patients without prior chemotherapy for metastatic disease.
    As a single agent in patients who have failed an established 5-fluorouracil containing treatment regimen.
    For the treatment of patients with small cell lung cancer.
    For the treatment of patients with gastric cancer.


    Contra-Indications

    Hypersensitivity to the active substance or to any of the excipients.
    Chronic inflammatory bowel disease and/or bowel obstruction.
    Pregnancy and lactation.
    Bilirubin > 3 times the ULN.
    Severe bone marrow failure.
    WHO performance status > 2.
    Concomitant use with St John’s Wort.


    Pregnancy and Lactation

    Contraindicated in pregnancy and lactation.


    Manufacturer
    Actavis Group, Iceland
    CLOSE